NEW YORK, April 4, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Medtronic, Inc. (NYSE: MDT), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), DaVita, Inc. (NYSE: DVA), Thermo Fisher Scientific, Inc. (NYSE: TMO), and Medicines Co. (NASDAQ: MDCO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
--
Medtronic, Inc. Analyst Notes
On March 31, 2014, Medtronic, Inc. (Medtronic) announced the final follow up results from the CoreValve® CE Pivotal Study, which demonstrated long-term durability and excellent clinical performance of the CoreValve System with no incidences of structural valve dysfunction at four years. The results were presented for the first time at the 63rd Annual Scientific Session of the American College of Cardiology. The Company informed that the study also displayed significant improvements in quality of life at one year which were sustained through four years, with 74% of patients improving at least one New York Heart Association (NYHA) functional class from baseline to four years. Medtronic stated that the CoreValve System was designed specifically to overcome the challenges of a broad range of TAVR patients and was approved by the U.S. Food and Drug Administration (FDA) in January 2014 for patients considered extreme risk for surgery; the device is not currently approved in the U.S. for use with patients at high risk. The full analyst notes on Medtronic, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04042014/MDT/report.pdf
--
Alexion Pharmaceuticals, Inc. Analyst Notes
On April 1, 2014, the shares of Alexion Pharmaceuticals, Inc. (Alexion) ended 2.11% higher at $155.34. The stock opened at $153.21, and oscillated in the range of $151.86 and 161.50. A total of 1.78 million shares changed hands during the day. Over the past 12 months, the stock has increased by 56.86%, outperforming the Nasdaq Composite which gained 31.13% during the same period. The full analyst notes on Alexion Pharmaceuticals, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04042014/ALXN/report.pdf
--
DaVita, Inc. Analyst Notes
On April 1, 2014, DaVita, Inc. (DaVita) gained for the third consecutive day and ended higher by 0.71% at $69.34. The stock opened at $69.00 and vacillated in the range of $68.71 and $69.55. The stock is trading near its 52-week high of $70.68. The volume of DaVita's stock traded was 3.22 million shares during the day. Over the past 12 months, the shares of DaVita increased 15.64% as compared to the NYSE Composite which increased 16.22% during the same period. The full analyst notes on DaVita, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04042014/DVA/report.pdf
--
Thermo Fisher Scientific, Inc. Analyst Notes
On March 31, 2014, Thermo Fisher Scientific, Inc. (Thermo Fisher Scientific) announced the introduction of new instruments, equipment, consumables and software at Analytica, the international trade fair for laboratory technology, analysis and biotechnology. The Company informed that it will showcase its offerings under its Thermo Scientific and Unity Lab Services brands in booth 101 and its Life Technologies brand in booth 418 at Messe München from April 1, 2014 to April 4, 2014. Thermo Fisher Scientific will also unveil for the first time in Europe new laboratory products that allow customers to perform day-to-day tasks more efficiently. "The products we're showcasing at Analytica demonstrate how faster analysis, more accurate results and the ability to transform data into knowledge can create a competitive advantage for our customers in today's evolving marketplace," said Marc N. Casper, President and CEO of Thermo Fisher Scientific. The full analyst notes on Thermo Fisher Scientific, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04042014/TMO/report.pdf
--
Medicines Co. Analyst Notes
On March 31, 2014, Medicines Co. (Medicines) released an update on the Angiomax® (Bivalirudin) Patent Litigation. The Company informed that Judge Andrews in theU.S. District Court of Delawareissued his Trial Opinion in"TheMedicines Company versusHospira, Inc." - a case involvingHospira'sAbbreviated New Drug Applications (ANDAs) seeking approval to commercially manufacture, use or sell a generic version of TheMedicines Company'sAngiomax® bivalirudin drug product before the expiration of the patents covering this product. The court upheld the validity of the two patents in the case, and also found that Hospira had failed to prove that the patents were either anticipated and/or obvious. However, with respect to infringement, based on itsJuly 2013Markman Decision, the Court found thatHospira'sANDAs did not meet the "efficient mixing" claim limitation and thus did not infringe the asserted claims of the '727 and '343 patents. The announcement led to a sharp decline in Medicines' stock which ended at $24.02 on April 1, 2014, representing a decline of 15.48% from previous day's close. The full analyst notes on Medicines Co. are available to download free of charge at:
http://www.AnalystsReview.com/04042014/MDCO/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
